31 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 INTERVIEW Grifols has emphasised its commitment to expanding its parenteral CDMO services, predominantly in the small molecules injectable field. What strategies is the company adopting to reinforce its position in this market? And how does this align with the growing demand for small molecule injectable therapeutics? Grifols is actively expanding its contract development and manufacturing services, particularly focusing on small molecule injectables. Here are some key strategies we are adopting: High specialization in fill-finish small molecule injectables: Grifols is enhancing its capabilities in the development and manufacturing of sterile injectable drugs, including both concentrated and diluted parenteral formulations. This specialization allows us to cater to the growing demand for highquality, terminal-sterilized injectable drugs. Manufacturing sites are equipped with automated multi product lines to ensure efficiency and high standards in the production process. This automation supports the scalability and flexibility needed to meet diverse client requirements. Global experience and partnerships: leveraging over 100 years of expertise, Grifols collaborates with mid-size, big, and generic pharmaceutical companies. These partnerships help us deliver substantial value and maintain high standards of quality. Commitment to innovation and improvement: CDMO business is aligned with corporate values such as innovation and continuous improvement ensuring it stays ahead in the competitive CDMO market. These strategies align with the growing demand for small molecule therapeutics by providing agile and flexible outsourcing solutions, ensuring high-quality pharmaceutical development, and addressing the needs of both human and veterinary pharmaceuticals. How do you plan to differentiate Grifols from other CDMO providers? We prioritize building long-term partnerships with clients by offering personalized services, flexibility, and responsiveness to meet their specific needs. These initiatives and differentiators help us stand out in the competitive CDMO market and attract clients looking for reliable and innovative partners. Grifols offers end-to-end solutions, from development to commercial manufacturing, ensuring seamless project execution and reducing time-to-market for clients. With a strong emphasis on quality and regulatory compliance, we ensure high quality standards for all products, which is crucial in the increasingly regulated pharma/ biotech industry. Recently, Grifols revealed details of technology investments that enhance its CDMO capabilities. Can you go into more detail as to how these investments will improve efficiency, scalability, and client satisfaction in small molecule manufacturing? Grifols operates two FDA-and GMP-approved manufacturing sites in Spain, located in Barcelona and Murcia. These facilities are equipped with advanced technologies, including formfill-seal (FFS) lines for flexible polypropylene (PP) bags, which optimize drug manufacturing costs, reduce lead times, and enhance patient safety. Facilities are designed with sustainability in mind, incorporating energyefficient technologies and waste reduction strategies. This not only reduces the environmental footprint but also aligns with the sustainability goals of many clients. The in-house engineering division, Grifols Engineering, provides additional support, helping in terms of control over the entire process. The new investments include additional FFS lines and highcapacity autoclaves for terminal sterilization. This expansion allows Grifols to scale up production efficiently to meet increasing client demands. New integrated artificial vision OCR systems (Optic Recognition of the characters) for particle detection ensures a high quality standard for injectable solutions assuring 100% vials inspected. This technology minimizes human intervention, reducing contamination risks and errors. These investments improve efficiency by streamlining production processes and enhancing quality control. Scalability is achieved through expanded capacity and advanced technologies, allowing us to handle larger volumes and more complex projects. Client A sponsor of DCAT Week expands on Parenteral CDMO services
RkJQdWJsaXNoZXIy MjY2OTA4MA==